Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2013

Open Access 01-12-2013 | Research

High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma

Authors: Yong-Ping Yang, Jian-Hui Qu, Xiu-Juan Chang, Yin-Ying Lu, Wen-Lin Bai, Zheng Dong, Hong Wang, Lin-Jing An, Zhong-Xian Xu, Chun-Ping Wang, Zhen Zeng, Ke-Qin Hu

Published in: Journal of Translational Medicine | Issue 1/2013

Login to get access

Abstract

Background

Cryoablation is one of the local therapies for hepatocellular carcinoma (HCC), but its safety and effect has not been studied in patients with Child class A or B and Barcelona Clinic Liver Cancer (BCLC) stage C HCC. Metastasis-associated in colon cancer-1 (MACC1) overexpression has been associated with poor prognosis of HCC, but its predictive value to post-cryoablation outcomes remains unknown in patients with BCLC stage C HCC.

Methods

This study assessed the safety and outcomes of cryoablation measured by time to progression (TTP) and overall survival (OS), and predictive value of MACC1 mRNA and protein overexpression in tumorous tissue to post-cryoablation outcomes in 120 advanced HCC patients with child-pugh class A or B by quantitative polymerase chain reaction and immunohistochemical staining. The potenial correlation of MACC1 and c-Met expression to tumor cell proliferation and apoptosis was also analyzed.

Results

The cryoablation in patients with advanced unresectable HCC resulted in a median TTP and OS of 5.5 (4.2- 6.7) months and 10.5 (9.0-12.0) months, respectively and no significant complications, comparable to the historical report for RFA therapy. The MACC1 mRNA and nuclear protein expression was significantly increased in tumorous tissues in these patients than that in normal liver tissue controls. Higher expression of MACC1 mRNA and nuclear protein in tumorous tissues in these patients was associated with shorter post cryoablation median TTP and OS than that with lower MACC1 expression.

Conclusions

Cryoablation is a safe and effective therapeutic option for patients with advanced HCC and Child-pugh class A or B cirrhosis; and a higher intratumoral expression of MACC1 or nuclear translocation predicts poor outcomes of cryotherapy in these patients.
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics. CA cancer. 2002, 55: 74-108.CrossRef
2.
Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology. 2005, 42: 1208-1236. 10.1002/hep.20933.CrossRefPubMed
3.
Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM: Survival analysis of 904 patinets with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol. 2008, 23: 467-473. 10.1111/j.1440-1746.2007.05112.x.CrossRefPubMed
4.
Llovet JM, Fuster J, Bruix J: Barcelona-clinic liver cancer group: The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004, 10 (suppl 1): S115-S120.CrossRefPubMed
5.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A: SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359: 378-390. 10.1056/NEJMoa0708857.CrossRefPubMed
6.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10: 25-34. 10.1016/S1470-2045(08)70285-7.CrossRefPubMed
7.
Zuro LM, Staren ED: Cryosurgical ablation of unresectable hepatic tumors. AORN J. 1996, 64: 231-236. 239–244CrossRefPubMed
8.
Wong WS, Patel SC, Cruz FS: Cryosurgery as a Treatment for Advanced Stage Hepatocellular Carcinoma. Results, Complications, and Alcohol Ablation. Cancer. 1998, 82: 1268-1278. 10.1002/(SICI)1097-0142(19980401)82:7<1268::AID-CNCR9>3.0.CO;2-B.CrossRefPubMed
9.
Osada S, Imai H, Tomita H: Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol. 2007, 95: 491-498. 10.1002/jso.20712.CrossRefPubMed
10.
Zhou L, Wang CP, Lu YY, Bai WL, Qu JH, Lou M, Zeng Z, Wu Y, Chen Y, Wang H: Decrease in size of non-treated lesions after cryoablation for hepatocellular carcinoma. Hepatogastroenterology. 2012, 59: 252-254.PubMed
11.
Zhou L, Fu JL, Lu YY, Fu BY, Wang CP, An LJ, Wang XZ, Zeng Z, Zhou CB, Yang YP: Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol. 2010, 45: 968-978. 10.1007/s00535-010-0243-3.CrossRefPubMed
12.
Chen HW, Lai EC, Zhen ZJ, Cui WZ, Liao S, Lau WY: Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma. Int J Surg. 2011, 9: 188-191. 10.1016/j.ijsu.2010.11.008.CrossRefPubMed
13.
Sabel MS: Cryo-immunology: A review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology. 2009, 58: 1-11. 10.1016/j.cryobiol.2008.10.126.CrossRefPubMed
14.
Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM: MACC1, a newly identified key regulator of HGF/Met signaling, predicts colon cancer metastasis. Nat Med. 2009, 15: 59-67. 10.1038/nm.1889.CrossRefPubMed
15.
Shirahata A, Shinmura K, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G: MACC1 as a Marker for Advanced Colorectal Carcinoma. Anticancer Res. 2010, 30: 2689-2692.PubMed
16.
Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G: MACC 1 as a Marker for Peritoneal-disseminated Gastric Carcinoma. Anticancer Res. 2010, 30: 3441-3444.PubMed
17.
Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY: Overexpression of Metastasis-Associated in Colon Cancer-1 Predicts a Poor Outcome of HBV-Related Hepatocellular Carcinoma. World J Gastroenterol. 2012, 18: 2995-3003. 10.3748/wjg.v18.i23.2995.PubMedCentralCrossRefPubMed
18.
Qiu JL, Huang PZ, Liu Q, Hong J, Li BK, Lu CL, Wang L, Wang JP, Yuan YF: Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011, 9: 166-175. 10.1186/1479-5876-9-166.PubMedCentralCrossRefPubMed
19.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-247. 10.1016/j.ejca.2008.10.026.CrossRefPubMed
20.
Lee HS, Kim JK, Cheong JY, Han EJ, An SY, Song JH, Jung YJ, Jeon SC, Jung MW, Jang EJ: Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis. Korean J Hepatol. 2010, 16: 369-375. 10.3350/kjhep.2010.16.4.369.PubMedCentralCrossRefPubMed
21.
Yamamoto J, Kosuge T, Saiura A, Sakamoto Y, Shimada K, Sano T, Takayama T, Sugawara Y, Yamaguchi T, Kokudo N: Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan Criteria. Jpn J Clin Ocncol. 2007, 34: 287-295.CrossRef
22.
Wang CP, Lu YY, Chen Y, Feng YY, An LJ, Wang XZ, Su SH, Bai WL, Zhou L, Yang YP: Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clin Exp Metastasis. 2009, 26: 839-848. 10.1007/s10585-009-9283-6.CrossRefPubMed
23.
Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM: New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006, 25: 3848-3856. 10.1038/sj.onc.1209548.CrossRefPubMed
24.
Yang YP, Wang CP, Lu YY, Bai WL, An LJ, Qu JH, Gao XD, Chen Y, Zhou L, Wu Y: Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012, 19: 674-684. 10.1007/s00534-011-0490-6.PubMedCentralCrossRefPubMed
25.
Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed
26.
Wang ZL, Liang P, Dong BW, Yu XL, Yu DJ: Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg. 2008, 12: 327-337. 10.1007/s11605-007-0310-0.CrossRefPubMed
27.
Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ: The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol. 2003, 21: 4329-4335. 10.1200/JCO.2003.11.137.CrossRefPubMed
28.
Lopez PM, Villanueva A, Llovet JM: Systematic review: evidence-based management of hepatocellular carcinoma–an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006, 23: 1535-1547. 10.1111/j.1365-2036.2006.02932.x.CrossRefPubMed
29.
Ng KK, Lam CM, Poon RT, Shek TW, To JY, Wo YH, Ho DW, Fan ST: Comparison of systemic responses of radiofrequency ablation, cryotherapy, and surgical resection in a porcine liver model. Ann Surg Oncol. 2004, 11: 650-657. 10.1245/ASO.2004.10.027.CrossRefPubMed
30.
Machi J, Bueno RS, Wong LL: Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg. 2005, 29: 1-10. 10.1007/s00268-004-1086-y.CrossRef
31.
Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J, Barcelona Clínic Liver Cancer Group: Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004, 40: 1352-1360. 10.1002/hep.20465.CrossRefPubMed
32.
Raut CP, Izzo F, Marra P, Ellis LM, Vauthey JN, Cremona F, Vallone P, Mastro A, Fornage BD, Curley SA: Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005, 12: 616-628. 10.1245/ASO.2005.06.011.CrossRefPubMed
33.
Callstrom MR, Charboneau JW: Technologies for ablation of hepatocellular carcinoma. Gastroenterology. 2008, 134: 1831-1835. 10.1053/j.gastro.2008.05.022.CrossRefPubMed
34.
Orlacchio A, Bazzocchi G, Pastorelli D, Bolacchi F, Angelico M, Almerighi C, Masala S, Simonetti G: Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience. Cardiovasc Intervent Radiol. 2008, 31: 587-594. 10.1007/s00270-008-9293-9.CrossRefPubMed
35.
Shimizu T, Sakuhara Y, Abo D, Hasegawa Y, Kodama Y, Endo H, Shirato H, Miyasaka K: Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2009, 16: 816-823. 10.1007/s00534-009-0124-4.CrossRefPubMed
36.
Allaf ME, Varkarakis IM, Bhayani SB, Inagaki T, Kavoussi LR, Solomon SB: Pain control requirements for percutaneous ablation of renal tumors:cryoablation versus radiofrequency ablation–initial observations. Radiology. 2005, 237: 366-370. 10.1148/radiol.2371040829.CrossRefPubMed
37.
Wang CP, Wang H, Qu JH, Lu YY, Bai WL, Dong Z, Gao XD, Rong GH, Zeng Z, Yang YP: Tumour seeding after percutaneous cryoablation for hepatocellular carcinoma. World J Gastroenterol. 2012, 18: 6587-6596. 10.3748/wjg.v18.i45.6587.PubMedCentralCrossRefPubMed
38.
Llovet JM, Vilana R, Brú C, Bianchi L, Salmeron JM, Boix L, Ganau S, Sala M, Pagès M, Ayuso C, Barcelona Clínic Liver Cancer (BCLC) Group: Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001, 33: 1124-1129. 10.1053/jhep.2001.24233.CrossRefPubMed
39.
Yu J, Liang P, Yu XL, Cheng ZG, Han ZY, Mu MJ, Wang XH: US-guided percutaneous microwave ablation of renal cell carcinoma: intermediate-term results. Eur J Radiol. 2012, 263: 900-908.
40.
Kerkar S, Carlin AM, Sohn RL, Steffes C, Tyburski J, Littrup P, Weaver D: Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. Surgery. 2004, 136: 770-779. 10.1016/j.surg.2004.07.001.CrossRefPubMed
41.
Sohn RL, Carlin AM, Steffes C, Tyburski JG, Wilson RF, Littrup PJ, Weaver DW: The extent of cryosurgery increases the complication rate after hepatic cryoablation. Am Surg. 2003, 69: 317-323.PubMed
42.
Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z: Cryotherapy is associated with improved clinical outcomes of sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012, 63: 159-169. 10.1007/s12013-012-9353-2.PubMedCentralCrossRefPubMed
43.
Kadouchi K, Higuchi K, Shiba M, Okazaki H, Yamamori K, Sasaki E, Tominaga K, Watanabe T, Fujiwara Y, Oshitani N: What are the risk factors for aggravation of esophageal varices in patients with hepatocellular carcinoma?. J Gastroenterol Hepatol. 2007, 22: 240-246. 10.1111/j.1440-1746.2006.04418.x.CrossRefPubMed
44.
Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH: Establishment of cell clones with different metastatic potential from the metastatic hepatocellularcarcinoma cell line MHCC97. World J Gastroenterol. 2001, 7: 630-636.PubMed
45.
Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H: MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res. 2011, 31: 777-780.PubMed
46.
Si MS, Amersi F, Golish SR, Ortiz JA, Zaky J, Finklestein D, Busuttil RW, Imagawa DK: Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival. Am Surg. 2003, 69: 879-885.PubMed
47.
Kang HY, Shin HD, Kim SB, Song IH: Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area. Clin Res Hepatol Gastroenterol. 2012, 36: 357-364. 10.1016/j.clinre.2011.12.018.CrossRefPubMed
48.
Tandon P, Garcia-Tsao G: Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009, 29: 502-508. 10.1111/j.1478-3231.2008.01957.x.PubMedCentralCrossRefPubMed
Metadata
Title
High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma
Authors
Yong-Ping Yang
Jian-Hui Qu
Xiu-Juan Chang
Yin-Ying Lu
Wen-Lin Bai
Zheng Dong
Hong Wang
Lin-Jing An
Zhong-Xian Xu
Chun-Ping Wang
Zhen Zeng
Ke-Qin Hu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-11-41

Other articles of this Issue 1/2013

Journal of Translational Medicine 1/2013 Go to the issue

Research

Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial

Research

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells

Methodology

Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer

Research

Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles

Research

Circulating microRNA: a novel potential biomarker for early diagnosis of Intracranial Aneurysm Rupture a case control study

Review

Cytokine-induced killer cells promote antitumor immunity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits